Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Versluis, J; In't Hout, F E; Devillier, R; van Putten, W L; Manz, M G; Vekemans, M C; Legdeur, M C; Passweg, J R; Maertens, J; Kuball, J; Biemond, B J; Valk, P J; van der Reijden, B A; Meloni, G; Schouten, H C; Vellenga, E; Pabst, T; Willemze, R; Löwenberg, B; Ossenkoppele, G; Baron, F; Huls, G; Cornelissen, J J (2016). Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia, 31(1):26-33.

Cornelissen, J J; Versluis, J; Passweg, J R; van Putten, W L; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J; van Marwijk, Kooy M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M C; Breems, D A; Verdonck, L F; Fey, M F; Jongen-Lavrencic, M; Janssen, J J; Huls, G; Kuball, J; Pabst, T; Graux, C; Schouten, H C; Gratwohl, A; Vellenga, E; Ossenkoppele, G; Löwenberg, B (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5):1041-1050.

Schlenk, R F; Taskesen, E; van Norden, Y; Krauter, J; Ganser, A; Bullinger, L; Gaidzik, V I; Paschka, P; Corbacioglu, A; Göhring, G; Kündgen, A; Held, G; Götze, K; Vellenga, E; Kuball, J; Schanz, U; Passweg, J; Papst, T; Maertens, J; Ossenkoppele, G J; Delwel, R; Döhner, H; Cornelissen, J J; Döhner, K; Löwenberg, B (2013). The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood, 9(122):1576-1582.

Vellenga, E; van Putten, W; Ossenkoppele, G J; Verdonck, L F; Theobald, L F; Cornelisson, J J; Huijgens, P C; Maertens, J; Gratwohl, A; Schaafsma, R; Schanz, U; Graux, C; Schouten, H C; Ferrant, A; Bargetzi, M; Fey, M F; Löwenberg, B (2011). Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood, 118(23):6037-6042.

Löwenberg, B; Pabst, T; Vellenga, E; van Putten, W; Schouten, H C; Graux, C; Ferrant, A; Sonneveld, P; Biemond, B J; Gratwohl, A; de Greef, G E; Verdonck, L F; Schaafsma, M R; Gregor, M; Theobald, M; Schanz, U; Maertens, J; Ossenkoppele, G J (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11):1027-1036.

Lugthart, S; Gröschel, S; Beverloo, H B; Kayser, S; Valk, P J; van Zelderen-Bhola, S L; Ossenkoppele, G J; Vellenga, E; van den Berg-de Ruiter, E; Schanz, U; Verhoef, G; Vandenberghe, P; Ferrant, A; Köhne, C H; Pfreundschuh, M; Horst, H A; Schlegelberger, H; Jotterand, M; Krauter, J; Pabst, T; Theobald, M; Schlenk, R F; Delwel, R; Döhner, K; Löwenberg, B; Döhner, H (2010). Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Journal of Clinical Oncology, 28(24):3890-3899.

This list was generated on Sun Sep 24 11:24:26 2017 CEST.